The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Could well be but if they can get a deal tie up that would help matters, question is how far away are they from a deal and will they need a raise by the time they get one
Well known twitter tipster bought in reason 4 rise, as a trade
Broker values +60p on deal
Hi Terry,
Take it you didn't read the recent RNS....
Headcount has been reduced by 40%, the overall variable costs of the business lowered and, as a result, the cash runway now extends into 2024
Well director buys so what do they know?
Hi,
Do you think this is a manufactured rise? Almost twice the 3 month average volume which is a lot given the volumes sold in December. You are probably right, it is difficult to believe that good news has leaked out to a rapturous waiting investment community. I’m still 86% down. Hey ho.
Well there do appear to be quite a few chunky sales of 50,000 or so this morning, hence the further strengthening of the SP. Hopefully a sign of good things to come!
I think they will buy in these small amounts but often.
In fairness, that is two Directors now....although still a few hundred thousand shares short of a purchase size that would encourage me to buy more personally. I agree with theoldmansdoneit's sentiment on this. Better than no purchases though, which makes them more worthy of respect than 90% of AIM BODs for this alone, IMO. I really hope they get a big return on it. Which would also result in me perhaps getting my own small stake back. Who knows? One deal and we might even make a small profit here, although given the cash runway, this is the spin of a roulette wheel now. Again IMO. GLA.
Interesting what one relatively small share purchase from a Board member will do to the share price! Makes you wonder what would happen if there was some definitively good news...
Whilst partnering appears the right and only route, our noval exosome delivery mechanism is possibly a decade away from FDA approval. So I guess the sixty four million dollar question is, does Mr Ross continue to try and fund Rene by various means for that period; something that many, including institutions, may have little appetite for given the experience of the last decade or does he try to sell?
The question then of course is to who and at what price? Novel therapies become exponentially more valuable over time but we don’t appear to be anywhere near a Phase 1 trial so what price would Ross and his Board off load the stock for? Sadly I haven’t the inside track of some so I’ve no idea but possibly dimes not dollars!
I still have faith that Iain will turn this ship around - if anyone can, he can, IMO...but it will take a much larger buy than that for me to add to my own position here. He bought bigger numbers of shares previously and at much higher prices, after all.
I agree theoldmansdoneit. Was thinking exact same things.
Guessing his purchase was the 9.5 trade @ 10:34 today.
Worth keeping an eye on.
I see that our executive Chairman Iain Ross has bought 100,000 shares today. It only amounts to c. £10,000 so not an overwhelming vote of confidence. If he’d bought a million I’d be more reassured. Still, if we could get a commercial deal or two over the line, it could easily be a ten bagger for him from these lowly levels.
LOL, I like your sense of humour Surprised.
Thanks Sajy, it’s good to have you back! It’s clear you’ve an inside track, a direct wire into Mr Ross’ office; in future it would be useful if you could as a result give us a heads up in advance of these RNS’. Thanks in anticipation.
My thoughts after this mornings Rns. Cash runway into 2024, which is a start, but I would like to see the hRPC data package sold for a few million and last I heard was that quite a few companies were interested. A few million should come from the Fosun partnerships. That should extend runway into mid 2024. I should point out that Fosun are paying the wages of a few of our staff as part of the deal. Regarding the exosomes our costs are paid for by partners and with no trials running our cash burn should be much lower this year. That should give them plenty of time to prove up the data and sign at least one exosome deal this year. We just need to get one deal over the line with a decent upfront payment and that will be transformational for the company. I still hold all my shares and believe Iain will turn it around, he is not going anywhere until he has. GLA.
Rene can sometimes feel like San Quentin’s antechamber but Mr Ross has intervened - we’ve been saved! Pinning his colours to the mast, runway extended, the auditors kept at bay, certainly for a while, we have another nine months at least to punctuate this board with our hopes and dreams. Fingers crossed once again; have a great end to the week.
IMO that is a very positive update. Not saying this is a screaming buy, or anything like that, but I think this shows strong business leadership - and yes, also gives an idea of how the business was probably run prior to his joining. Not buying anymore, unless Iain does first, but not selling my small holding here either. I want to see how this plays out. GLA.
Sounds ruthless, but probably needs to be. Perhaps says a lot about how the company was being run beforehand.
Mr Ross is getting to grips with the business. Cash runway extended to 2024 . 'In addition, we plan to discontinue, out-license and/or dispose of all the Company's legacy assets. We will provide further updates in due course'.
Very well put Surprised 2
Probably most stockholders are aware of this latest objective, as they have been over the last decade and more of other such dreams. There is a general hope however that like a broken clock they’ll deliver at least once.
The concern is time is running out unless there is either further dilution, which they failed to achieve in the latter part of ‘22 or the runway is extended by some form of industry collaboration, which is the gist of the latest aspiration.
Of course what no one is presently illuminating is what an extended runway represents, should it be achieved, other than more time and more research! Something that Rene has been very good at for the last fifteen years. Something that has been awesome for those presenting at conferences, less so for those wanting to make a turn on their dollar.
Outlook
With the executive team now in place, the key focus over the coming period for myself and the rest for the team will be data generation and collaboration deals to further extend the cash runway.
We are targeting to announce several larger scale exosome collaborations from existing / new partners and to develop further collaboration agreements with our iPSC platform. We also plan to accelerate the number of partnering opportunities in the 'hopper' through a greater focus on marketing of the advantages of the CustomExTM platform. This, I believe, will lead to further success for the Company over the longer term.
There is only a number of times you can go the the shareholder well before it dries up. He will have to go elsewhere to find the cash hope it is not at the shareholder expense